Pentazocine-naloxone experimenters among abusers of pentazocine and tripelennamine from a VA treatment population.
Psychiatric diagnostic profiles, drug and personal histories, and social support measures were obtained for a clinic sample of abusers of pentazocine when the drug was withdrawn and re-released by the manufacturer compounded with the opiate antagonist naloxone. Nearly 50% of the sample (N = 99) reported using the new drug during the following 6 to 9 months, despite its reduced abuse potential. Reinterviews revealed that claimed use of pentazocine dropped to half.
True
W R
WR
Veterans Administration Medical Center, St. Louis, Missouri 63125.
Poklis
A
A
Jamieson
R W
RW
Seyfried
W
W
D000328:Adult; D006801:Humans; D008297:Male; D009270:Naloxone / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000523:psychology / Q000534:rehabilitation*; D010423:Pentazocine; D011379:Prognosis; D012944:Social Support; D014309:Tripelennamine
D009270:Naloxone; D014309:Tripelennamine; D010423:Pentazocine